Clinical evaluation of [99mTc]Tc-PSMA-P1: a promising SPECT radiotracer for prostate cancer imaging

Q: What type of study is this?

This is a In Vitro Study study.

Maria Hassan; Tanveer Hussain Bokhari; Faiz Ahmed; Yun‐Sang Lee; Nadeem Ahmed Lodhi

doi:10.1039/d5ra04397b

January 1, 2025RSC AdvancesOpen Access

Clinical evaluation of [99mTc]Tc-PSMA-P1: a promising SPECT radiotracer for prostate cancer imaging

View Full Paper

Ask AI

Bookmark

Share

Key Points

Prostate cancer detection is enhanced using the novel PSMA-P1 radiotracer, improving imaging outcomes.
Key evidence shows that Technetium-99m radiolabeling leads to significant advancements in prostate cancer imaging.
The approach involves synthesizing a PSMA inhibitor and formulating a radiolabeled kit for enhanced imaging capabilities.
These findings support the use of PSMA-P1 as a promising tool in prostate cancer diagnostics, a crucial advancement in oncology.

Implication

SPECT analysis demonstrates improved prostate cancer detection with PSMA-P1, suggesting its potential as a diagnostic tool.

Abstract

This study aimed to design and synthesize a prostate-specific membrane antigen inhibitor (PSMA-P1) and to formulate a freeze-dried kit for radiolabeling with Technetium-99m ( 99m Tc) to improve prostate cancer detection.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hassan et al. (2025) studied this question.

synapsesocial.com/papers/68a6fb9e5502675167ba9928 https://doi.org/10.1039/d5ra04397b

View Full Paper

Ask AI

Bookmark

Share

Clinical evaluation of [99mTc]Tc-PSMA-P1: a promising SPECT radiotracer for prostate cancer imaging

Key Points

Implication

Abstract

Discussion

Cite This Study

Clinical evaluation of [99mTc]Tc-PSMA-P1: a promising SPECT radiotracer for prostate cancer imaging

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading